Effects of the COVID-19 pandemic on the consumption of antiretrovirals and HIV/AIDS prevention indicators at the Treichville University Hospital (Ivory Coast)
Abstract
Objective: To understand the impact of Covid-19 on the prevention and consumption of antiretroviral drugs at Treichville University Hospital.
Methods: This was a retrospective cross-sectional study with a descriptive, multicenter aim, carried out in six screening and treatment departments for HIV patients at the Treichville University Hospital. Monthly order reports from January 2019 to December 2021 from six services were used to collect data on screening and antiretroviral treatment. After a univariate analysis, an Anova made it possible to carry out a comparison of several variables between the study periods.
Results: In total, a decrease of 40 to 55% (p>0.05) in the consumption of antiretrovirals was recorded compared to 2019. The antiretrovirals affected more specifically were tenofovir 300mg, lamivudine 150 mg, abacavir / adult lamivudine, lopiritonavir and the tenofovir / adult lamivudine combination (p<0.05). Therapeutic protocols and prevention data varied between 2019 and 2021 with a drop in the prescription of dolutegravir to the profile of efavirenz and a drop of 17.5% of individuals screened in 2020.
Conclusion: The Covid-19 health crisis has led to a drop in the frequency of HIV testing and a non-significant effect on the consumption of antiretrovirals essential for the management of the disease.
Keywords: Covid-19; Antiretrovirals; Prevention; HIV
Keywords:
Covid-19, Antiretrovirals, Prevention, HIVDOI
https://doi.org/10.22270/jddt.v14i4.6504References
Details HIV/AIDS; 2021. Disponible sur https://www.who.int/fr/news-room/facts-in-pictures/detail/hiv-aids . Consulté le 10 Juin 2022.
Palella FJJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, « Declining Morbidity and Mortality among Pateints with Advanced Human Immunodeficiency Virus Infection » News England Journal of Medicine, 1998; (41):433-445.
CEDEAO. Stratégie Régionale pour le VIH, la Tuberculose, les Hépatites B & C et les Droits et Santé Sexuels et Reproductifs des Populations Clés de la CEDEAO. 2020.p.67.
ONUSIDA Côte d’ivoire; 2020. Available at https://www.unaids.org/fr/regionscountries/countries/ctedivoire. Accessed June 11, 2022.
HIV/AIDS; 2022. Available at https://www.who.int/fr/health-topics/hiv-aids#tab. Accessed June 10, 2022.
Coronavirus Disease (COVID-19) situation report-64; 2020. Available at https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200324-sitrep-64-covid-19.pdf?sfvrs n=703b2c40_2. Accessed March 22, 2020.
Direction générale de la santé. Note circulaire N°0002/2019/MSHP/DGS/PNLS/SST/Km portant directives techniques de prévention du sida et de prise en charge des personnes vivant avec le VIH. DGS; 2019.p.9.
International treatement preparedness coalition-West Africa. Enquête rapide sur les besoins des PVVIH dans le contexte du COVID-19 en Côte d’Ivoire. ITPC-WA; 2020.p.4.
Chippaux JP, « Impact de la COVID-19 sur la santé publique en Afrique subsaharienne ». Bulletin de l’Académie Nationale de Médecine, 2022; 207:150-164. https://doi.org/10.1016/j.banm.2022.10.015 PMid:36628105 PMCid: PMC9816877
Weill A, Douin J, Desplas D, Cuenot F, Dray-Spira R, Zyreik M. Usage des médicaments de ville en France durant l’épidémie de la Covid-19 – point de situation après les 8 semaines de confinement et une semaine de post-confinement. ANSM; 2020.p.312.
Programme national de lutte contre le Sida. Evaluation des effets de la crise à Covid-19 sur l’offre et la demande des services VIH en Côte d’Ivoire. PNLS; 2021.p.73.
Organisation Mondiale de la Santé. Enquête Pulse sur la continuité des services de santé essentiels pendant la pandémie à COVID-19: OMS: rapport intérimaire du 27 août 2020; 2020.p.41.
Published
Abstract Display: 313 
PDF Downloads: 182 PDF Downloads: 16 How to Cite
Issue
Section
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.